Sagimet Biosciences Inc. (SGMT), on Monday announced the appointment of Andreas Grauer as Chief Medical Officer, effective April 20.
Eduardo Bruno Martins has retired as CMO and will continue to support the company as an external scientific advisor.
Andreas Grauer brings more than two decades of experience in clinical development, medical affairs, and regulatory strategy, and most recently served as Chief Medical Officer at Omeros Corp. (OMER).
The company said the appointment is expected to support the advancement of its FASN inhibitor pipeline and broader clinical development programs.
In the pre-market trading, Sagimet Biosciences Inc is 0.31% lesser at $6.45 on the Nasdaq.
In the pre-market trading, Omeros is 0.22% lesser at $13.41 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.